The pharmacokinetics of mitomycin C in the mitomycin C, ifosfamide and cisplatin (MIC) regimen

Highley, M.S.; Harper, B.; Harper, P.G.; Dumez, H.; Guetens, G.; De Boeck, G.; Prenen, H.; Schrijvers, D.; Maes, R.A.A.; De Bruijn, E.A.

doi:10.3923/IJP.2006.293.297

Title

The pharmacokinetics of mitomycin C in the mitomycin C, ifosfamide and cisplatin (MIC) regimen

Author

Highley, M.S.

Harper, B.

Harper, P.G.

Dumez, H.

Guetens, G.

De Boeck, G.

Prenen, H.

Schrijvers, D.

Maes, R.A.A.

De Bruijn, E.A.

Abstract

The purpose of this study was to investigate the pharmacokinetics of mitomycin C when administered with ifosfamide and cisplatin as part of the mitomycin C, ifosfamide and cisplatin (MIC) regimen. Eleven patients with advanced non-small cell lung cancer, aged 49-73 years, were treated with mitomycin C (6 mg m-2), ifosfamide and cisplatin. Mitomycin C concentrations in plasma and erythrocytes were determined using HPLC with UV absorbance detection at 360 nm. The plasma β half life of mitomycin C was 44 min and the clearance 16.38 L h-1 m-2. A mean erythrocyte/plasma ratio of 0.87 (SD±0.35) was obtained. At low plasma concentrations, mitomycin C was undetectable in the erythrocyte. The mean plasma mitomycin C concentration when this occurred was 50 ng mL-1 (SD±35). The plasma pharmacokinetics of mitomycin C in the MIC regimen are consistent with the pharmacokinetic data obtained as a single agent, or as a component of other chemotherapy regimens. Mitomycin C is taken up into erythrocytes and is detectable within these cells for two hs following injection. The erythrocyte may act as a transporter of this compound in the circulation.

Language

English

Source (journal)

International journal of pharmacology. - -

Publication

2006

ISSN

1811-7775

DOI

10.3923/IJP.2006.293.297

Volume/pages

2 :3 (2006) , p. 293-297